title: Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.
abstract: The purpose of this paper was to determine the cardiac status in children 15 years or more after adriamycin therapy for a solid tumour. Of the 447 pts, 229 pts were fully studied and 218 were not. The following cardiac evaluations were proposed to all the 447 consecutive patients (pts): (1) cardiac Doppler US by one of two expert cardiologists; (2) cardiac rhythm and conduction abnormalities including 24-hour holter ECG; (3) (131)l-mlBG myocardial scintigraphy; (4) serum brain natriuretic peptide levels at rest; (5) an exercise test with VO(2) max measurement. The radiation doses delivered to 6 points in the heart were estimated for all patients who had received radiotherapy. Congestive heart failure was diagnosed in 24 of 229 (10%) evaluated pts, with a median interval of 15 years (0.3-24 years) from the first symptom after adriamycin treatment. Among the 205 remaining pts, 13 asymptomatic pts (6%) had severe (n=4) (FS<20%) or marked (n=9) (20< or =FS<25%) systolic dysfunction. In the 192 others, the median meridional end-systolic wall stress was 91 (53-135) and it exceeded 100 g cm(-2) in 52 pts. Using a Cox model, only the cumulative dose of adriamycin and the average radiation dose to the heart, were identified as risk factors for a pathological cardiac status. In conclusion, the risk of cardiac failure or severe abnormalities increases with adriamycin treatment, radiotherapy and time since treatment, even after a follow-up of 15 years or more. In our series, after an average follow-up of 18 years, 39% of the children had a severe cardiac dysfunction or major ventricular overload conditions. The risk increases with the dose of adriamycin and radiation received to the heart, without evidence for threshold.
authors.affiliation: Department of Paediatric Oncology, Institut Gustave Roussy, rue Camille Desmoulins 39, 94805 Villejuif, France. pein@igr.fr
authors.forename: F
authors.initials: F
authors.lastname: Pein
authors.forename: O
authors.initials: O
authors.lastname: Sakiroglu
authors.forename: M
authors.initials: M
authors.lastname: Dahan
authors.forename: J
authors.initials: J
authors.lastname: Lebidois
authors.forename: P
authors.initials: P
authors.lastname: Merlet
authors.forename: A
authors.initials: A
authors.lastname: Shamsaldin
authors.forename: E
authors.initials: E
authors.lastname: Villain
authors.forename: F
authors.initials: F
authors.lastname: de Vathaire
authors.forename: D
authors.initials: D
authors.lastname: Sidi
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011832:Radiation Injuries; D012307:Risk Factors; D017741:Survivors; D013997:Time Factors; D018487:Ventricular Dysfunction, Left
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin